Stabilized composition comprising at least one adrenergic compound

A method for stabilizing a liquid pharmaceutical composition comprising an adrenergic compound as the sole therapeutically active ingredient, comprising the steps of i) providing a solution of an adrenergic compound, wherein the adrenergic compound is epinephrine or a physiologically acceptable salt thereof, ii) adding at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite, and a sulfite compound, iii) adjusting the pH thereof to a value in the range 2.0-5.0 optionally by addition of an acid or a base, wherein the liquid pharmaceutical composition is a liquid solution and the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30.

A method of stabilizing a liquid pharmaceutical composition which comprises combining at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite, and a sulfite compound and epinephrine or a physiologically acceptable salt thereof, wherein epinephrine or a physiologically acceptable salt thereof is the sole therapeutically active ingredient, the liquid pharmaceutical composition is a liquid solution, the molar ratio of the epinephrine or a physiologically acceptable salt thereof to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and the pH of said liquid composition is in the range of 2.0-5.0.

A kit comprising:

• i) a liquid pharmaceutical composition comprising an adrenergic compound as the sole therapeutically active ingredient, wherein the adrenergic compound is epinephrine or a physiologically acceptable sale thereof, and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound, wherein the liquid pharmaceutical composition is a liquid solution, the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and the pH of said liquid composition is in the range of 2.0-5.0, and
• ii) an administration device.

A method of improving at least one symptom of a medical condition requiring an adrenergic compound in an individual in need thereof, which comprises administering to the individual a liquid pharmaceutical composition comprising an adrenergic compound as the sole therapeutically active ingredient, wherein the adrenergic compound is epinephrine or a physiologically acceptable salt thereof, and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound, wherein the liquid pharmaceutical composition is a liquid solution, the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and the pH of said liquid composition is in the range of 2.0-5.0.

A method of treating anaphylaxis in an individual comprising administering to the individual a liquid pharmaceutical composition comprising an adrenergic compound as the sole therapeutically active ingredient, wherein the adrenergic compound is epinephrine or a physiologically acceptable salt thereof, and at least one antioxidant selected from the group consisting of a bisulfite, a metabisulfite and a sulfite compound, wherein the liquid pharmaceutical composition is a liquid solution, the molar ratio of the adrenergic compound to the at least one antioxidant, measured as sulfite-equivalents, is in the range 0.70-1.30, and the pH of said liquid composition is in the range of 2.0-5.0.